Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Glypican 3 Protein-VLP (GPC3) (AA 438-554)

GPC3 Origine: Humain Hôte: HEK-293 Cells VLP > 95 % as determined by HPLC Imm, ELISA, Func, SPR Active
N° du produit ABIN7448166
  • Antigène Voir toutes Glypican 3 (GPC3) Protéines
    Glypican 3 (GPC3)
    Type de proteíne
    VLP
    Activité biologique
    Active
    Attributs du protein
    AA 438-554
    Origine
    • 21
    • 6
    • 6
    • 4
    • 1
    Humain
    Source
    • 24
    • 7
    • 3
    • 2
    • 1
    • 1
    HEK-293 Cells
    Application
    Immunogen (Imm), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
    Fonction
    Human GPC3 Protein-VLP
    Séquence
    Arg438-Asn554
    Attributs du produit
    Recombinant Human GPC3 (438-554) Protein-VLP is expressed from HEK293.It contains Arg438-Asn554.
    Pureté
    > 95 % as determined by HPLC
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1EU per μg by the LAL method.
    Biological Activity Comment
    Immobilized Human GPC3 (438-554) VLP at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-GPC3 Antibody, hFc Tag with the EC50 of 24.1ng/ml determined by ELISA.
    Top Product
    Discover our top product GPC3 Protéine
  • Indications d'application
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    Commentaires

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    Stock
    -80 °C
    Stockage commentaire
    Valid for 12 months from date of receipt when stored at -80°C.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Date de péremption
    12 months
  • Antigène
    Glypican 3 (GPC3)
    Autre désignation
    GPC3 (GPC3 Produits)
    Synonymes
    GPC3 Protein, sgb Protein, dgsx Protein, sdys Protein, sgbs Protein, oci-5 Protein, sgbs1 Protein, DGSX Protein, GTR2-2 Protein, MXR7 Protein, OCI-5 Protein, SDYS Protein, SGB Protein, SGBS Protein, SGBS1 Protein, Glypican-3 Protein, glypican 3 Protein, gpc3 Protein, GPC3 Protein, Gpc3 Protein
    Sujet
    Glypican-3 is a protein ,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed.
    Poids moléculaire
    21.5 kDa.
    Pathways
    Glycosaminoglycan Metabolic Process
Vous êtes ici:
Support technique